Passage Bio Announces Appointment of William Chou, M.D. as Chief Executive Officer

October 10, 2022

https://www.globenewswire.com/news-release/2022/10/10/2530868/0/en/Passage-Bio-Announces-Appointment-of-William-Chou-M-D-as-Chief-Executive-Officer.html

PHILADELPHIA, Oct. 10, 2022 (GLOBE NEWSWIRE) — Passage Bio, Inc. (Nasdaq:PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced the appointment of William Chou, M.D. as chief executive officer (CEO) and a member of the board, effective immediately. Edgar B. (Chip) Cale will resign his position as the company’s interim CEO and will continue in his role as general counsel and corporate secretary. Maxine Gowen, Ph.D., will step down as interim executive chairwoman following a brief transition period and will then continue to serve as chairwoman.

Read more at globenewswire.com

Related news for (PASG)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.